Back
 Health  Vol.10 No.8 , August 2018
Crystal Structures of Human 17β-Hydroxysteroid Dehydrogenase Type 1 Complexed with the Dual-Site Inhibitor EM-139
Abstract: Human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the biosynthesis of the most potent natural estrogen 17β-estradiol (E2) from estrone (E1) in the ovary and peripheral tissues, playing a pivotal role in the progression of estrogen-dependent diseases. N-n-Butyl-N-methyl-ll-(16'α-chloro-3',17'β-dihydroxyestra-1',3',5'(10')-trien-7'α-yl)undecanamide (EM-139) was previously described as a dual-site inhibitor that can inhibit 17β-HSD1 transforming E1 into E2 and also inhibit estrogen receptor. In the present report, we describe the co-crystallization of EM-139 with 17β-HSD1 as well as the analysis of the three-dimensional structure of the enzyme/inhibitor complex. The crystal is grown under similar condition as native crystals, whereas the space group is changed to I121 never observed in other 17β-HSD1 crystals before. The steroidal moiety of the bound EM-139 molecule has shown a binding pattern similar to E2 in the E2 binary complex. The O-3 of the inhibitor develops hydrogen bonds with residues His221 and Glu282, whereas the O-17 makes hydrogen bonds with Ser142 and Tyr155. The bulky 7α-alkyl moiety of the inhibitor, which is essential for its anti-estrogenic activity but cannot be defined in the electron density, may compromise the inhibitory effect of EM-139 to 17β-HSD1. Moreover, the 16α-Cl atom shows no obvious interaction with surrounding residues. The atomic level understanding of the inhibitory mechanism of EM-139 provides important information for the inhibitor design of 17β-HSD1, which will facilitate future development of more potent and selective inhibitors of the enzyme for therapeutic purposes.
Cite this paper: Li, T. , Zhu, D. , Labrie, F. and Lin, S. (2018) Crystal Structures of Human 17β-Hydroxysteroid Dehydrogenase Type 1 Complexed with the Dual-Site Inhibitor EM-139. Health, 10, 1079-1089. doi: 10.4236/health.2018.108081.
References

[1]   Luu-The, V., Labrie, C., Zhao, H.F., Couet, J., Lachance, Y., Simard, J., Leblanc, G., Coté, J., Bérubé, D. and Gagné, R. (1989) Characterization of cDNAs for Human Estradiol 17beta-Dehydrogenase and Assignment of the Gene to Chromosome 17: Evidence of Two mRNA Species with Distinct 5'-Termini in Human Placenta. Molecular Endocrinology, 3, 1301-1309.
https://doi.org/10.1210/mend-3-8-1301

[2]   Miyoshi, Y., Ando, A., Shiba, E., Taguchi, T., Tamaki, Y. and Noguchi, S. (2001) Involvement of Up-Regulation of 17beta-Hydroxysteroid Dehydrogenase Type 1 in Maintenance of Intratumoral High Estradiol Levels in Postmenopausal Breast Cancers. International Journal of Cancer, 94, 685-689.
https://doi.org/10.1002/ijc.1525

[3]   Lin, S.X., Chen, J., Mazumdar, M., Poirier, D., Wang, C., Azzi, A. and Zhou, M. (2010) Molecular Therapy of Breast Cancer: Progress and Future Directions. Nature Reviews Endocrinology, 6, 485-493.
https://doi.org/10.1038/nrendo.2010.92

[4]   Cornel, K.M., Kruitwagen, R.F., Delvoux, B., Visconti, L., Van de Vijver, K.K., Day, J.M., Van Gorp, T., Hermans, R.J., Dunselman, G.A. and Romano, A. (2012) Overexpression of 17beta-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17beta-Estradiol. The Journal of Clinical Endocrinology & Metabolism, 97, E591-E601.
https://doi.org/10.1210/jc.2011-2994

[5]   Konings, G.F., Cornel, K.M., Xanthoulea, S., Delvoux, B., Skowron, M.A., Kooreman, L., Koskimies, P., Krakstad, C., Salvesen, H.B., van Kuijk, K., Schrooders, Y.J., Vooijs, M., Groot, A.J., Bongers, M.Y., Kruitwagen, R.F., ENITEC and Romano, A. (2018) Blocking 17beta-Hydroxysteroid Dehydrogenase Type 1 in Endometrial Cancer: A Potential Novel Endocrine Therapeutic Approach. The Journal of Pathology, 244, 203-214.
https://doi.org/10.1002/path.5004

[6]   Delvoux, B., D’Hooghe, T., Kyama, C., Koskimies, P., Hermans, R.J., Dunselman, G.A. and Romano, A. (2014) Inhibition of Type 1 17beta-Hydroxysteroid Dehydrogenase Impairs the Synthesis of 17beta-Estradiol in Endometriosis Lesions. The Journal of Clinical Endocrinology & Metabolism, 99, 276-284.
https://doi.org/10.1210/jc.2013-2851

[7]   Mori, T., Ito, F., Matsushima, H., Takaoka, O., Koshiba, A., Tanaka, Y., Kusuki, I. and Kitawaki, J. (2015) Dienogest Reduces HSD17beta1 Expression and Activity in Endometriosis. Journal of Endocrinology, 225, 69-76.
https://doi.org/10.1530/JOE-15-0052

[8]   Smuc, T., Pucelj, M.R., Sinkovec, J., Husen, B., Thole, H. and Rizner, T.L. (2009) Expression Analysis of the Genes Involved in Estradiol and Progesterone Action in Human Ovarian Endometriosis. Gynecological Endocrinology, 23, 105-111.
https://doi.org/10.1080/09513590601152219

[9]   Blomquist, C.H., Bonenfant, M., McGinley, D.M., Posalaky, Z., Lakatua, D.J., Tuli-Puri, S., Bealka, D.G. and Tremblay, Y. (2002) Androgenic and Estrogenic 17β-Hydroxysteroid Dehydrogenase/17-Ketosteroid Reductase in Human Ovarian Epithelial Tumors: Evidence for the Type 1, 2 and 5 Isoforms. The Journal of Steroid Biochemistry and Molecular Biology, 81, 343-351.
https://doi.org/10.1016/S0960-0760(02)00117-6

[10]   Gunnarsson, C., Olsson, B.M. and Stal, O.; S. S. B. C. Group (2001) Abnormal Expression of 17beta-Hydroxysteroid Dehydrogenases in Breast Cancer Predicts Late Recurrence. Cancer Research, 61, 8448-8451.

[11]   Vihko, P., Harkonen, P., Soronen, P., Torn, S., Herrala, A., Kurkela, R., Pulkka, A. Oduwole, O. and Isomaa, V. (2004) 17beta-Hydroxysteroid Dehydrogenases—Their Role in Pathophysiology. Molecular and Cellular Endocrinology, 215, 83-88.
https://doi.org/10.1016/j.mce.2003.11.021

[12]   Salhab, M., Reed, M.J., Al Sarakbi, W., Jiang, W.G. and Mokbel, K. (2006) The Role of Aromatase and 17-Beta-Hydroxysteroid Dehydrogenase Type 1 mRNA Expression in Predicting the Clinical Outcome of Human Breast Cancer. Breast Cancer Research and Treatment, 99, 155-162.
https://doi.org/10.1007/s10549-006-9198-8

[13]   Poirier, D. (2010) 17β-Hydroxysteroid Dehydrogenase Inhibitors: A Patent Review. Expert Opinion on Therapeutic Patents, 20, 1123-1145.
https://doi.org/10.1517/13543776.2010.505604

[14]   Lin, S.X., Poirier, D. and Adamski, J. (2013) A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study. Current Topics in Medicinal Chemistry, 13, 1164-1171.
https://doi.org/10.2174/15680266113139990004

[15]   Trottier, A., Maltais, R., Ayan, D., Barbeau, X., Roy, J., Perreault, M., Poulin, R., Lague, P. and Poirier, D. (2017) Insight into the Mode of Action and Selectivity of PBRM, a Covalent Steroidal Inhibitor of 17beta-Hydroxysteroid Dehydrogenase Type 1. Biochemical Pharmacology, 144, 149-161.
https://doi.org/10.1016/j.bcp.2017.08.004

[16]   Day, J.M., Tutill, H.J., Purohit, A. and Reed, M.J. (2008) Design and Validation of Specific Inhibitors of 17beta-Hydroxysteroid Dehydrogenases for Therapeutic Application in Breast and Prostate Cancer, and in Endometriosis. Endocrine-Related Cancer, 15, 665-692.
https://doi.org/10.1677/ERC-08-0042

[17]   Poirier, D. (2011) Contribution to the Development of Inhibitors of 17beta-Hydroxysteroid Dehydrogenase Types 1 and 7: Key Tools for Studying and Treating Estrogen-Dependent Diseases. The Journal of Steroid Biochemistry and Molecular Biology, 125, 83-94.
https://doi.org/10.1016/j.jsbmb.2010.12.007

[18]   Brozic, P., Lanisnik Risner, T. and Gobec, S. (2008) Inhibitors of 17beta-Hydroxysteroid Dehydrogenase Type 1. Current Medicinal Chemistry, 15, 137-150.
https://doi.org/10.2174/092986708783330629

[19]   Levesque, C., Merand, Y., Dufour, J. M., Labrie, C. and Labrie, F. (1991) Synthesis and Biological Activity of New Halo-Steroidal Antiestrogens. Journal of Medicinal Chemistry, 34, 1624-1630.
https://doi.org/10.1021/jm00109a014

[20]   Lin, S.X., Han, Q., Azzi, A., Zhu, D.W., Gangloff, A. and Campbell, R.L. (1999) 3D-Structure of Human Estrogenic 17β-HSD1: Binding with Various Steroids. The Journal of Steroid Biochemistry and Molecular Biology, 69, 425-429.
https://doi.org/10.1016/S0960-0760(99)00062-X

[21]   Labrie, C., Martel, C., Dufour, J.M., Lévesque, C., Mérand, Y. and Labrie, F. (1992) Novel Compounds Inhibit Estrogen Formation and Action. Cancer Research, 52, 610-615.

[22]   Poirier, D. (2003) Inhibitors of 17β-Hydroxysteroid Dehydrogenases. Current Medicinal Chemistry, 10, 453-477.
https://doi.org/10.2174/0929867033368222

[23]   Zhu, D.W., Campbell, R., Labrie, F. and Lin, S.X. (1999) Crystallization and Preliminary Crystal Structure of the Complex of 17β-Hydroxysteroid Dehydrogenase with a Dual-Site Inhibitor. The Journal of Steroid Biochemistry and Molecular Biology, 70, 229-235.
https://doi.org/10.1016/S0960-0760(99)00111-9

[24]   Breton, R., Yang, F., Jin, J.Z., Li, B., Labrie, F. and Lin, S.X. (1994) Human 17β-Hydroxysteroid Dehydrogenase: Overproduction Using a Baculovirus Expression System and Characterization. The Journal of Steroid Biochemistry and Molecular Biology, 50, 275-282.
https://doi.org/10.1016/0960-0760(94)90132-5

[25]   Lin, S.X., Yang, F., Jin, J.Z., Breton, R., Zhu, D.W., Luu-The, V. and Labrie, F. (1992) Subunit Identity of the Dimeric 17 Beta-Hydroxysteroid Dehydrogenase from Human Placenta. Journal of Biological Chemistry, 267, 16182-16187.

[26]   Zhu, D.W., Azzi, A., Rehse, P. and Lin, S.X. (1996) The Crystallogenesis of a Human Estradiol Dehydrogenase-Substrate Complex. Journal of Crystal Growth, 168, 275-279.
https://doi.org/10.1016/0022-0248(96)00331-4

[27]   Leslie, A.G.W. and Powell, H.R. (2007) Processing Diffraction Data with Mosflm. Springer, Berlin.
https://doi.org/10.1007/978-1-4020-6316-9_4

[28]   Evans, P. (2006) Scaling and Assessment of Data Quality. Acta Crystallographica Section D Biological Crystallography, 62, 72-82.
https://doi.org/10.1107/S0907444905036693

[29]   Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., McNicholas, S.J., Murshudov, G.N., Pannu, N.S., Potterton, E.A., Powell, H.R., Read, R.J., Vagin, A. and Wilson, K.S. (2011) Overview of the CCP4 Suite and Current Developments. Acta Crystallographica Section D Biological Crystallography, 67, 235-242.
https://doi.org/10.1107/S0907444910045749

[30]   Vagin, A. and Teplyakov, A. (2010) Molecular Replacement with MOLREP. Acta Crystallographica Section D Biological Crystallography, 66, 22-25.
https://doi.org/10.1107/S0907444909042589

[31]   Gangloff, A., Shi, R., Nahoum, V. and Lin, S.X. (2003) Pseudo-Symmetry of C19 Steroids, Alternative Binding Orientations, and Multispecificity in Human Estrogenic 17beta-Hydroxysteroid Dehydrogenase. FASEBJ, 17, 274-276.
https://doi.org/10.1096/fj.02-0397fje

[32]   Murshudov, G.N., Vagin, A.A., Lebedev, A., Wilson, K.S. and Dodson, E.J. (1999) Efficient Anisotropic Refinement of Macromolecular Structures Using FFT. Acta Crystallographica Section D Biological Crystallography, 55, 247-255.
https://doi.org/10.1107/S090744499801405X

[33]   Emsley, P., Lohkamp, B., Scott, W.G. and Cowtan, K. (2010) Features and Development of Coot. Acta Crystallographica Section D Biological Crystallography, 66, 486-501.
https://doi.org/10.1107/S0907444910007493

[34]   Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thornton, J.M. (1993) PROCHECK: A Program to Check the Stereochemical Quality of Protein Structures. Journal of Applied Crystallography, 26, 283-291.
https://doi.org/10.1107/S0021889892009944

[35]   Kleywegt, G.J. and Jones, T.A. (1996) Phi/Psi-Chology: Ramachandran Revisited. Structure, 4, 1395-1400.
https://doi.org/10.1016/S0969-2126(96)00147-5

[36]   Aka, J.A., Mazumdar, M., Chen, C.Q., Poirier, D. and Lin, S.X. (2010) 17beta-Hydroxysteroid Dehydrogenase Type 1 Stimulates Breast Cancer by Dihydrotestosterone Inactivation in Addition to Estradiol Production. Molecular Endocrinology, 24, 832-845.
https://doi.org/10.1210/me.2009-0468

[37]   Azzi, A., Rehse, P.H., Zhu, D.W., Campbell, R.L., Labrie, F. and Lin, S.X. (1996) Crystal Structure of Human Estrogenic 17β-Hydroxysteroid Dehydrogenase Complexed with 17β-Estradiol. Nature Structural Biology, 3, 665-668.
https://doi.org/10.1038/nsb0896-665

[38]   Breton, R., Housset, D., Mazza, C. and Fontecilla-Camps, J.C. (1996) The Structure of a Complex of Human 17b-Hydroxysteroid Dehydrogenase with Estradiol and NADP+ Identifies Two Principal Targets for the Design of Inhibitors. Structure, 4, 905-915.
https://doi.org/10.1016/S0969-2126(96)00098-6

[39]   Shi, R. and Lin, S.X. (2004) Cofactor Hydrogen Bonding onto the Protein Main Chain Is Conserved in the Short Chain Dehydrogenase/Reductase Family and Contributes to Nicotinamide Orientation. The Journal of Biological Chemistry, 279, 16778-16785.
https://doi.org/10.1074/jbc.M313156200

[40]   Sawicki, M.W., Erman, M., Puranen, T., Vihko, P. and Ghosh, D. (1999) Structure of the Ternary Complex of Human 17beta-Hydroxysteroid Dehydrogenase Type 1 with 3-Hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proceedings of the National Academy of Sciences, 96, 840-845.
https://doi.org/10.1073/pnas.96.3.840

[41]   Zhu, D.W., Han, Q., Qiu, W., Campbell, R., Xie, B.X., Azzi, A. and Lin, S.X. (1999) Human 17β-Hydroxysteroid Dehydrogenase-Ligand Complexes: Crystals of Different Space Groups with Various Cations and Combined Seeding and Co-Crystallization. Journal of Crystal Growth, 196, 356-364.
https://doi.org/10.1016/S0022-0248(98)00848-3

[42]   Ghosh, D., Pletnev, V.Z., Zhu, D.W., Wawrzak, Z., Duax, W.L., Pangborn, W., Labrie, F. and Lin, S.X. (1995) Structure of Human Estrogenic 17 Beta-Hydroxysteroid Dehydrogenase at 2.20 A Resolution. Structure, 3, 503-513.
https://doi.org/10.1016/S0969-2126(01)00183-6

[43]   Wakeling, A.E. and Bowler, J. (1989) Biology and Mode of Action of Pure Antioestrogens. Journal of Chemotherapy, 1, 1140-1141.

 
 
Top